New York – October 23, 2019 – As one of the world’s leading chemical suppliers in the last two decades, BOC Sciences announces to release varieties of EGFR inhibitors this month for scientists and researchers who are devoted to drug R&D of cancer treatment. This type of inhibitors can be used as medicine for a range of cancers, NSCLC in particular, through a mechanism of binding to certain parts of the EGFR and slow down or stop cell growth.
EGFR, short for epidermal growth factor receptor, is a membrane-bound protein found on the surface of certain types of cells. It plays a key role in cell growth and survival. In cancer cells, EGFR is observed to be at abnormally high levels, and activation of tumor cell EGFR through autophosphorylation can give rise to unregulated cell division of cancer cells, possibly through a series of intracellular events like cell proliferation, invasion and metastasis, which are all hallmarks of carcinogenesis.
“In clinical practice, two types of drugs that affect EGFR are used, that is, tyrosine kinase inhibitors, which include erlotinib, gefitinib, and lapatinib, and monoclonal antibodies such as panitumumab and cetuximab,” commented Prof. Jones, a senior scientist from BOC Sciences. “Tyrosine kinase inhibitors (TKIs) work through intracellular binding and subsequent inhibition of EGFR signaling pathways, and are usually administered orally. In contrast, monoclonal antibodies are given intravenously and work through mechanism of extracellular binding with subsequent inhibition of EGFR signaling pathways.”
EGFR inhibitors can be used for the treatment of varieties of indications and diseases. Currently, the following five EGFR inhibitors are approved by FDA, including Cetuximab, Erlotinib, Gefitinib, Lapatinib, and Panitumumab. In fact, EGFR inhibitors can be used in combination with other therapies like chemotherapy, biological agents, or radiotherapy. Previous in vivo studies showed that by combing erlotinib with other biological agents, such as mTOR inhibitor rapamycin, HDAC inhibitors or proteasome inhibitor bortezomib, additive antitumor activity is observed yet with no increased toxicity.
However, it should be noted that EGFR as a medicinal therapy does not work for all patients. Recent researches have proved that people with mutations in KRAS and NRAS may not benefit from EGFR-involved drugs. “We’ve released almost one hundred EGFR inhibitors, which cover the most researched ones as well as those with rare access to,” adds Prof. Jones. “As always, our mission is to provide high quality small molecules to facilitate the research projects of our customers worldwide, hoping that they can explore a more effective EGFR-based therapy as soon as possible so that more patients may benefit from it.”
For more information about EGFR inhibitors at BOC Sciences, please visit https://www.bocsci.com.
About BOC Sciences
With high-profiled experts specialized in multi-disciplines like drug discovery, chemistry and life science, BOC Sciences is a reliable vendor of a comprehensive collection of chemicals for scientists and researchers in both academia and industry. Over the last twenty years, it has gained a fame as well as valuable trust from customers worldwide in the supply of chemicals like small molecule inhibitors, APIs, pharmaceutical excipients, intermediates and natural compounds. In addition, it also provides all-stage-covering drug R&D services to support the pharmaceutical industry.
Company Name: BOC Sciences
Contact Person: Alex Brown
Email: Send Email
Phone: 1631 619 7922
Address:45-16 Ramsey Road, Shirley
State: NY 11967
Country: United States